MapLight Therapeutics

1 articles
The Motley FoolThe Motley Fool··Sarah Sidlow

MapLight CFO Dumps $1M in Stock as Biotech Posts Deepening Losses

MapLight Therapeutics CFO sold 36,371 shares worth $1.02M via pre-arranged plan, reducing holdings 9.3% while stock surged 70.8% annually.
MPLTclinical-stage biotechCNS disorders